Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Grail

3 Biotech Stocks to Monitor for May Moves

The biotech industry is well poised to flourish, buoyed by its strong emphasis on technology-driven advancements to address complex medical challenges and government funding. Hence, quality biotech stocks Harmony Biosciences Holdings (HRMY), Illumina (ILMN), and Compugen (CGEN) could be ideal watchlist additions for May. Read more….

StockNews.com

'You Know You’ve Still Got To Go Through Hell To Get There, But If You Can Get It At Stage 2 or 3'... Hall Of Famer Juli Inkster On New Cancer Screening

Are we entering a new worldwide era for cancer screening?

Golf Monthly

Illumina Sheds Light, Divests its Cancer Tester, Grail

Illumina, a beacon in genetic science, is set to unfurl its stake in Grail-the stellar creator of cancer-detecting tests–in a dance of corporate divestiture.

Top News

From analysis to the latest developments in health,
read the most diverse news in one place.

3 Healthcare Stocks to Buy With Major Value Behind Them

The healthcare industry is set for growth due to the growing demand for quality healthcare services and the integration of advanced technologies in offerings and operations. Therefore, it could be wise to buy fundamentally strong medical stocks HCA Healthcare (HCA), LifeVantage (LFVN), and Semler Scientific (SMLR). Read more….

StockNews.com

EU orders biotech giant Illumina to unwind $7.1 billion purchase of cancer-screening company Grail

The European Union is ordering U.S. biotech giant Illumina to undo its $7.1 billion purchase of cancer-screening company Grail because it closed the deal without approval of regulators

The Independent UK

Inside Illumina’s bruising proxy battle with billionaire activist investor Carl Icahn

Illumina’s contentious acquisition of cancer test maker Grail brought billionaire Carl Icahn to the company’s doorstep.

Fortune

EU fines US firm Illumina $475 million for jumping gun on buying cancer-screening company Grail

The European Union has slapped a $475 million fine on U.S. biotech giant Illumina for buying out cancer-screening company Grail without the approval of the 27-nation bloc’s antitrust watchdog

The Independent UK

Read news from The Economist, FT, and more,
with one subscription

Illumina’s Sudden CEO Exit Is Just One of Many Problems Facing DNA Company

The sudden resignation of Francis deSouza raises questions about the firm’s future after its proxy fight with Carl Icahn.

Businessweek

Carl Icahn’s activist play plays into the hands of Lina Khan and EU regulators

Every company with acquisition plans in the U.S. and Europe should be concerned about the FTC partnering with EU regulators to sink the Illumina-Grail deal.

Fortune

Canyon Grail CF SL 7 eTap review – gravel bike with a need for speed

We put one of Canyon's fast and light gravel bikes to the test and see how it rides outside its comfort zone

Bike Perfect

A frozen capital market and an insurance premium shock: 10 health care predictions for 2023 from top investors

Distressed deals, inflation in insurance premiums, and restrictions on transgender treatments. Here's what the health care sector will look like in 2023, according to top investors.

Fortune

A blood test that screens for multiple cancers at once promises to boost early detection

Detecting cancer early before it spreads throughout the body can be lifesaving. This is why doctors recommend regular screening for several common cancer types, using a variety of methods. Colonoscopies, for example, screen for colon cancer, while mammograms screen for breast cancer.

The Conversation

Faye Flam: Better cancer screenings are coming. Can we afford them?

Patients and their doctors count on cancer screening tests to save lives, and yet a number of large, controlled studies are showing disappointing results for mammography and other mass screening tests. This month, the New England Journal of Medicine published a controversial study that cast doubt on the widely accepted…

Tribune News Service

European regulators move to block Illumina's $7.1 billion acquisition of Grail

Europe's antitrust regulator on Tuesday moved to block San Diego's Illumina from acquiring Grail — one week after a U.S. administrative law judge found that the blockbuster $7.1 billion merger should be allowed to stand.

Tribune News Service

Get all your
news in one place.

100's of premium titles.
One news app.

Daily Mirror

New blood test claims to detect cancer cells before symptoms begin

Researchers believe the main cause for surging cancer rates is because humans are living longer. A new test is hoping to detect cancerous cells to allow for earlier treatment for the disease

Benzinga

Top Financial Stories Tuesday, September 6: Focus on iPhone 14 Event, OPEC+ Plans Mild Production Cut, Netflix Says No To Crypto Ads And More…

Reuters EQT Corp Close To Buying THQ Appalachia

Benzinga

Top Financial Stories Friday, September 2: GM's Cruise Recalls Some Robotaxis Over Software Glitch, Chinese Tech Giant Suffers $43M Impairment Loss On Bitcoin and Ethereum Holdings And More..

Wall Street Journal

The Conversation

Tech firms face more regulation after moves to stop 'killer' acquisitions – but innovation could also be under threat

One way to eliminate the competition in business is simply to buy them out and shut them down. And that means less choice for consumers and sometimes the loss of innovative and, in the case of the pharmaceutical industry, even life-saving products. But such so-called killer acquisitions are likely to…

Get all your
news in one place.

100's of premium titles.
One news app.

Tribune News Service

Biden’s FTC has blocked 4 hospital mergers and is poised to thwart more consolidation attempts

Fresh off the Federal Trade Commission’s successful challenges to four hospital mergers, the Biden administration’s new majority on the commission is primed to more aggressively combat consolidation in the health care industry than it has in past years.

Benzinga

Illumina Reports 41% Dip In Q1 Profits Despite 12% Jump in Sales, Reaffirms FY22 Guidance

Illumina Inc's (NASDAQ:ILMN) Q1 FY22 revenues rose 12% Y/Y to $1.22 billion, in line with estimates. Nearly all revenues came from the core Illumina business; GRAIL, Illumina's cancer liquid biopsy subsidiary, recorded revenues of $10 million. Product revenue for the quarter totaled $1.07 billion, up 12%, and Service and other revenue amounted to…

USA Today Sports Media Group

With Chevron leaving, PGA Tour Champions brings new golf tournament to Palm Springs area

The event will be played on the Dinah Shore Tournament Course at Mission Hills Country Club.

Chicago Sun-Times

Can ‘liquid biopsy’ cancer blood tests live up to promise of saving lives?

Research is under way even as one company touts its blood test to people with no signs of cancer as a way to detect tumors that have no recommended screening method.

The Independent UK

Can cancer blood tests live up to promise of saving lives?

A new type of blood test that checks for signs of cancer in healthy people has hit the market

1 2

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.